Upgrade to SI Premium - Free Trial

Ionis Pharmaceuticals (IONS)

74.48 -0.65 (0.87%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/5/26)

Latest Headlines

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses June 4, 2026 7:00 AM - BizWire Form 4 IONIS PHARMACEUTICALS For: Jun 01 Filed by: BERTHELSEN SPENCER R June 3, 2026 5:34 PM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: BERTHELSEN SPENCER R June 1, 2026 10:48 AM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS) June 1, 2026 6:57 AM - StreetInsider JPMorgan says large-cap biotech is back as profits and pipelines fuel upside May 28, 2026 4:07 PM - StreetInsider Form 8-K IONIS PHARMACEUTICALS For: May 28 May 28, 2026 12:41 PM - SEC Filing Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B May 28, 2026 4:45 AM - BizWire H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS) May 27, 2026 6:44 AM - StreetInsider Wolfe: 'Arrowhead Q3 data in acute pancreatitis will be the next big event to readthrough to Ionis. We see 74% odds of IONS stock down, 26% odds up' May 26, 2026 5:33 AM - StreetInsider JPMorgan Reinstates Ionis Pharmaceuticals (IONS) at Overweight May 20, 2026 4:30 AM - StreetInsider Citi Starts Ionis Pharmaceuticals (IONS) at Buy May 18, 2026 4:15 PM - StreetInsider Form 4 IONIS PHARMACEUTICALS For: May 13 Filed by: Monia Brett P May 15, 2026 6:15 PM - SEC Filing Form SCHEDULE 13G/A IONIS PHARMACEUTICALS Filed by: T. Rowe Price Investment Management, Inc. May 15, 2026 10:07 AM - SEC Filing Form SCHEDULE 13G/A IONIS PHARMACEUTICALS Filed by: Capital World Investors May 14, 2026 1:56 PM - SEC Filing Biogen advances IONIS alzheimer's drug after phase 2 study shows cognitive benefit May 14, 2026 7:05 AM - StreetInsider Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer� May 14, 2026 7:05 AM - BizWire Form 144 IONIS PHARMACEUTICALS Filed by: Monia Brett P May 13, 2026 5:20 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: May 04 Filed by: LOSCALZO JOSEPH May 6, 2026 5:27 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: May 01 Filed by: KLEIN JOSEPH III May 5, 2026 4:31 PM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: LOSCALZO JOSEPH May 4, 2026 6:06 PM - SEC Filing Ionis to host 2026 virtual Annual Meeting of Stockholders May 4, 2026 7:05 AM - BizWire Ionis to present at upcoming investor conferences May 1, 2026 7:05 AM - BizWire Form 4 IONIS PHARMACEUTICALS For: Apr 28 Filed by: Baroldi Joseph April 30, 2026 4:26 PM - SEC Filing Form SCHEDULE 13G IONIS PHARMACEUTICALS Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 30, 2026 11:08 AM - SEC Filing Ionis Pharmaceuticals (IONS) PT Raised to $100 at RBC Capital April 30, 2026 8:39 AM - StreetInsider Ionis Pharmaceuticals (IONS) PT Raised to $96 at Bernstein SocGen Group April 30, 2026 7:36 AM - StreetInsider Ionis Pharmaceuticals (IONS) PT Raised to $125 at H.C. Wainwright April 30, 2026 6:50 AM - StreetInsider Ionis Pharmaceuticals (IONS) PT Raised to $115 at Barclays April 30, 2026 6:01 AM - StreetInsider Ionis Pharmaceuticals (IONS) PT Raised to $110 at Oppenheimer April 29, 2026 5:40 PM - StreetInsider Ionis Pharmaceuticals (IONS) PT Raised to $86 at Stifel April 29, 2026 4:10 PM - StreetInsider Form 10-Q IONIS PHARMACEUTICALS For: Mar 31 April 29, 2026 2:34 PM - SEC Filing Ionis Pharmaceuticals (IONS) Tops Q1 EPS by 29c ; Offers Guidance April 29, 2026 7:10 AM - StreetInsider Form 8-K IONIS PHARMACEUTICALS For: Apr 29 April 29, 2026 7:01 AM - SEC Filing Ionis reports first quarter 2026 financial results and highlights progress on key programs April 29, 2026 7:00 AM - BizWire Form 144 IONIS PHARMACEUTICALS Filed by: Baroldi Joseph April 28, 2026 4:13 PM - SEC Filing FDA accepts GSK's bepirovirsen for priority review in hepatitis B treatment April 28, 2026 2:06 AM - StreetInsider Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B April 28, 2026 2:06 AM - BizWire U.S. Biotech stocks: Q1 earnings previews April 26, 2026 8:00 PM - StreetInsider Form ARS IONIS PHARMACEUTICALS For: Dec 31 April 23, 2026 7:06 PM - SEC Filing Form DEFA14A IONIS PHARMACEUTICALS April 23, 2026 7:06 PM - SEC Filing Form DEF 14A IONIS PHARMACEUTICALS For: Jun 04 April 23, 2026 7:06 PM - SEC Filing Ionis Pharmaceuticals (IONS) PT Lowered to $108 at TD Cowen April 23, 2026 9:35 AM - StreetInsider Ionis Pharmaceuticals (IONS) PT Raised to $130 at Morgan Stanley April 21, 2026 8:15 AM - StreetInsider Ionis reports positive zilganersen data for Alexander disease April 21, 2026 7:03 AM - StreetInsider Form 8-K IONIS PHARMACEUTICALS For: Apr 21 April 21, 2026 7:02 AM - SEC Filing Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting April 21, 2026 7:00 AM - BizWire Canaccord Starts Ionis Pharmaceuticals (IONS) at Buy April 20, 2026 4:16 PM - StreetInsider Form 4 IONIS PHARMACEUTICALS For: Apr 15 Filed by: PARSHALL B LYNNE April 17, 2026 7:19 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Apr 15 Filed by: Jenne Kyle April 17, 2026 7:19 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Apr 15 Filed by: Birchler Brian April 17, 2026 7:19 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Apr 15 Filed by: Baroldi Joseph April 17, 2026 7:19 PM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: Jenne Kyle April 16, 2026 6:50 PM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: Birchler Brian April 16, 2026 6:48 PM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: Baroldi Joseph April 16, 2026 6:45 PM - SEC Filing Ionis to hold first quarter 2026 financial results webcast April 15, 2026 7:05 AM - BizWire Raymond James Starts Ionis Pharmaceuticals (IONS) at Outperform, 'Taking Returns to Heart (and Mind)' April 9, 2026 4:26 PM - StreetInsider Ionis Pharmaceuticals (IONS) PT Raised to $111 at BofA Securities April 9, 2026 8:56 AM - StreetInsider Form 4 IONIS PHARMACEUTICALS For: Apr 01 Filed by: KLEIN JOSEPH III April 2, 2026 7:44 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Apr 02 Filed by: Devers Shannon L. April 2, 2026 7:44 PM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: Diaz Allene M. March 31, 2026 5:28 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS) March 31, 2026 6:41 AM - StreetInsider FDA approves high dose SPINRAZA for spinal muscular atrophy March 30, 2026 7:30 AM - StreetInsider FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy March 30, 2026 7:30 AM - StreetInsider Form SCHEDULE 13G/A IONIS PHARMACEUTICALS Filed by: VANGUARD GROUP INC March 27, 2026 9:53 AM - SEC Filing William Blair stays Outperform on Ionis Pharmaceuticals (IONS); pricing update 'positive' March 25, 2026 5:45 PM - StreetInsider Ionis Pharmaceuticals (IONS) PT Raised to $106 at Barclays March 25, 2026 3:58 PM - StreetInsider RBC Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS) March 25, 2026 3:42 PM - StreetInsider BofA Securities stays Buy on Ionis Pharmaceuticals (IONS) as new pricing 'a positive update' March 25, 2026 12:24 PM - StreetInsider Ionis Pharmaceuticals (IONS) PT Raised to $83 at Stifel March 25, 2026 11:44 AM - StreetInsider Ionis Pharmaceuticals (IONS) PT Raised to $120 at H.C. Wainwright March 25, 2026 10:58 AM - StreetInsider Ionis Pharmaceuticals (IONS) PT Raised to $104 at Oppenheimer March 25, 2026 10:13 AM - StreetInsider Ionis Pharmaceuticals (IONS) PT Raised to $114 at Leerink Partners March 25, 2026 10:12 AM - StreetInsider Wolfe Research on Ionis Pharmaceuticals (IONS): new Tryngolza pricing likely to ‘squeeze’ Arrowhead’s rival drug March 25, 2026 9:46 AM - StreetInsider Form 144/A IONIS PHARMACEUTICALS Filed by: Schneider Eugene March 24, 2026 4:44 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Mar 19 Filed by: Schneider Eugene March 23, 2026 7:37 PM - SEC Filing FDA grants priority review to Ionis' Alexander disease treatment March 23, 2026 7:00 AM - StreetInsider Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review March 23, 2026 7:00 AM - BizWire Form 144 IONIS PHARMACEUTICALS Filed by: Schneider Eugene March 19, 2026 4:01 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Mar 16 Filed by: HOUGEN ELIZABETH L March 18, 2026 5:19 PM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: HOUGEN ELIZABETH L March 16, 2026 4:33 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Mar 09 Filed by: O'NEIL PATRICK R. March 11, 2026 4:19 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Mar 09 Filed by: Monia Brett P March 11, 2026 4:19 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Mar 10 Filed by: Jenne Kyle March 11, 2026 4:19 PM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: Jenne Kyle March 10, 2026 4:00 PM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: O'NEIL PATRICK R. March 9, 2026 4:17 PM - SEC Filing Form 8-K IONIS PHARMACEUTICALS For: Mar 03 March 9, 2026 7:02 AM - SEC Filing Ionis announces board changes with two retirements, one addition March 9, 2026 7:00 AM - StreetInsider Ionis announces changes to Board of Directors March 9, 2026 7:00 AM - BizWire Full Article List